Suchergebnisse - "Ziepert, Marita"

PubPharm (130)

121

Malignant Lymphomas - Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma — Analyses of cases from two prospectively randomized clinical trials

enthalten in: Haematologica, the hematology journal | 2009

von Bernd, H. | Ziepert, M. | Thorns, C. | +16

122

Equitoxicity of bolus and infusional etoposide : results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

enthalten in: Annals of hematology | 2008

von Zwick, C. | Birkmann, J. | Peter, N. | +35

123

MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas

enthalten in: British journal of haematology | 2008

von Roehle, A. | Hoefig, K. | Repsilber, D. | +12

CommentIn: Br J Haematol. 2009 Jan;144(1):138-40. - PMID 19016736

124

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

enthalten in: Annals of hematology | 2008

von Zwick, C. | Birkmann, J. | Peter, N. | +9

125

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

enthalten in: Annals of hematology | 2008

von Zwick, C. | Birkmann, J. | Peter, N. | +9

126

Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone)

enthalten in: Annals of hematology | 2008

von Zwick, C. | Birkmann, J. | Peter, N. | +9

127

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas : a randomised controlled trial (RICOVER-60)

enthalten in: The Lancet. Oncology | 2008

von Pfreundschuh, M. | Schubert, J. | Ziepert, M. | +24

CommentIn: Lancet Oncol. 2008 Feb;9(2):84-6. - PMID 18237844

128

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

enthalten in: The lancet / Oncology | 2008

von Pfreundschuh, M. | Schubert, J. | Ziepert, M. | +23

129

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

enthalten in: The lancet / Oncology | 2008

von Pfreundschuh, M. | Schubert, J. | Ziepert, M. | +16

130

MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas

enthalten in: British journal of haematology | 2008

von Roehle, A. | Hoefig, K. | Repsilber, D. | +12

[1]
« Vorheriger
3
4
5
6
7
8
9
10
11
12
13